Advisory Panel Backs Broad Boceprevir Label, But With Discussion Of Drug's Data Limitations
This article was originally published in The Pink Sheet Daily
Executive Summary
Members want physicians to make the decision on use for individual Hepatitis C patients despite lack of data on prior null responders.
You may also be interested in...
Merck To Ship Hepatitis C Drug Victrelis To Pharmacies Within A Week
Merck will begin shipping Victrelis (boceprevir) to pharmacies within a week, the company announced following FDA approval of the hepatitis C drug after market-close on May 13 – a time-frame that roughly coincides with expected FDA action on Vertex's Incivek (telaprevir).
Merck To Ship Hepatitis C Drug Victrelis To Pharmacies Within A Week
Merck will begin shipping Victrelis (boceprevir) to pharmacies within a week, the company announced following FDA approval of the hepatitis C drug after market-close on May 13 – a time-frame that roughly coincides with expected FDA action on Vertex's Incivek (telaprevir).
Merck To Ship Hepatitis C Drug Victrelis To Pharmacies Within A Week
FDA approves boceprevir, the first protease inhibitor for hepatitis C, without overly proscriptive labeling.